Literature DB >> 28035771

Hepatitis B virus infection and decreased risk of nonalcoholic fatty liver disease: A cohort study.

Eun-Jeong Joo1, Yoosoo Chang2,3,4, Joon-Sup Yeom1, Seungho Ryu2,3,4.   

Abstract

The presence of an association between chronic hepatitis B virus (HBV) infection and fatty liver is controversial. We examined the association between HBV infection and the development of nonalcoholic fatty liver disease (NAFLD). We conducted a cohort study of 83,339 participants without NAFLD at baseline who underwent serologic testing for hepatitis B surface antigen (HBsAg) between 2002 and 2006 and were followed annually or biennially until December 2014. NAFLD was defined as the presence of ultrasonographic fatty liver in the absence of excessive alcohol use or other identifiable causes. We used a parametric Cox model to estimate adjusted hazard ratios with 95% confidence intervals of incident NAFLD. During 484,736.1 person-years of follow-up, 20,200 incident NAFLD cases were identified. In models adjusted for age, sex, year of visit, smoking status, alcohol intake, regular exercise, education level, and body mass index, the adjusted hazard ratio (95% confidence interval) for incident NAFLD comparing HBsAg-positive to HBsAg-negative participants was 0.83 (0.73-0.94). After introducing HBV infection and confounders (including homeostasis model assessment of insulin resistance and metabolic factors) as time-dependent exposures, the association between HBV infection and decreased risk of incident NAFLD was attenuated but persisted. These associations were consistently observed across clinically relevant, prespecified subgroups.
CONCLUSION: In this large cohort of apparently healthy Korean adults, HBsAg seropositivity was associated with lower risk of developing NAFLD, indicating a possible effect of HBV infection on the pathogenesis of NAFLD development. (Hepatology 2017;65:828-835).
© 2016 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 28035771     DOI: 10.1002/hep.28917

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  36 in total

1.  Nonalcoholic fatty liver disease is associated with lower hepatitis B viral load and antiviral response in pediatric population.

Authors:  Lu Wang; Yijin Wang; Shuhong Liu; Xiangwei Zhai; Guangde Zhou; Fengmin Lu; Jingmin Zhao
Journal:  J Gastroenterol       Date:  2019-05-27       Impact factor: 7.527

2.  Clinical Characteristics and Outcome of Morbidly Obese Bariatric Patients with Concurrent Hepatitis C Viral Infection.

Authors:  Ming-Lun Han; Wei-Jei Lee; Jung-Chien Chen; Kong-Han Ser; Shu-Chun Chen; Yi-Chih Lee
Journal:  Obes Surg       Date:  2019-03       Impact factor: 4.129

3.  Fatty liver checkmates hepatitis B virus.

Authors:  Gayatri Ramakrishna; Nirupma Trehanpati
Journal:  Hepatol Int       Date:  2018-10-12       Impact factor: 6.047

4.  The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease.

Authors:  Mohammed Eslam; Shiv K Sarin; Vincent Wai-Sun Wong; Jian-Gao Fan; Takumi Kawaguchi; Sang Hoon Ahn; Ming-Hua Zheng; Gamal Shiha; Yusuf Yilmaz; Rino Gani; Shahinul Alam; Yock Young Dan; Jia-Horng Kao; Saeed Hamid; Ian Homer Cua; Wah-Kheong Chan; Diana Payawal; Soek-Siam Tan; Tawesak Tanwandee; Leon A Adams; Manoj Kumar; Masao Omata; Jacob George
Journal:  Hepatol Int       Date:  2020-10-01       Impact factor: 6.047

5.  Hepatitis B virus infection and risk of non-alcoholic fatty liver disease: A population-based cohort study.

Authors:  Liguo Zhu; Jie Jiang; Xiangjun Zhai; Aileen Baecker; Hong Peng; Jiao Qian; MingHao Zhou; Ci Song; Yan Zhou; Jianfang Xu; Hongjian Liu; Dong Hang; Zhibin Hu; Hongbin Shen; Zuo-Feng Zhang; Fengcai Zhu
Journal:  Liver Int       Date:  2018-08-19       Impact factor: 5.828

6.  Non-alcoholic hepatic steatosis attenuates hepatitis B virus replication in an HBV-immunocompetent mouse model.

Authors:  Danqing Hu; Hongwu Wang; Hai Wang; Yaqi Wang; Xiaoyang Wan; Weiming Yan; Xiaoping Luo; Qin Ning
Journal:  Hepatol Int       Date:  2018-07-05       Impact factor: 6.047

7.  Reduced hepatic steatosis is associated with higher risk of hepatocellular carcinoma in chronic hepatitis B infection.

Authors:  Lung-Yi Mak; Rex Wan-Hin Hui; James Fung; Fen Liu; Danny Ka-Ho Wong; Bofei Li; Ka-Shing Cheung; Man-Fung Yuen; Wai-Kay Seto
Journal:  Hepatol Int       Date:  2021-06-21       Impact factor: 6.047

8.  High Rates of Liver Cirrhosis and Hepatocellular Carcinoma in Chronic Hepatitis B Patients with Metabolic and Cardiovascular Comorbidities.

Authors:  Jan-Hendrik Bockmann; Matin Kohsar; John M Murray; Vanessa Hamed; Maura Dandri; Stefan Lüth; Ansgar W Lohse; Julian Schulze-Zur-Wiesch
Journal:  Microorganisms       Date:  2021-04-30

9.  Clinical and Histologic Features of Patients with Biopsy-Proven Metabolic Dysfunction-Associated Fatty Liver Disease.

Authors:  Shang-Chin Huang; Hau-Jyun Su; Jia-Horng Kao; Tai-Chung Tseng; Hung-Chih Yang; Tung-Hung Su; Pei-Jer Chen; Chun-Jen Liu
Journal:  Gut Liver       Date:  2021-05-15       Impact factor: 4.519

10.  Hepatic Steatosis and Steatohepatitis in a Large North American Cohort of Adults With Chronic Hepatitis B.

Authors:  Mandana Khalili; David E Kleiner; Wendy C King; Richard K Sterling; Marc G Ghany; Raymond T Chung; Atul K Bhan; Philip Rosenthal; Mauricio Lisker-Melman; Rageshree Ramachandran; Anna S Lok
Journal:  Am J Gastroenterol       Date:  2021-08-01       Impact factor: 12.045

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.